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Helicobacterpylori affects gastric acid secretion via several mechanisms. One
of these is by changing gastric regulatory physiology. The infection elevates
plasma gastrin levels and decreases gastric mucosal expression ofthe inhibito-
ry peptide somatostatin. These changes may be due to products of H. pyloni
itself or inflammatory cytokines released in H. pylori infection: acid secretion
is inhibited less by a low intra-gastric pH, infusions ofcholecystokinin and gas-
tric distention in infected persons. Eradication of H. pyloni rapidly decreases
basal acid secretion and gastrin-releasing, peptide-stimulated acid secretion.
There are now reports that maximally-stimulated acid secretion, a measure of
the parietal cell mass, falls significantly six and 12 months after eradication of
H. pylori from duodenal ulcer patients. This might be due to withdrawal ofthe
trophic effect ofgastrin. HoweverH. pylori can also decrease gastric acid secre-
tion, both through the mechanisms described in Dr. Cave's paper and by caus-
ing gastric mucosal atrophy with loss of parietal cells. The net effect on acid
presumably depends on which mechanism predominates. The processes
involved may be crucial determinants ofclinical outcome. For example, infec-
tion with little atrophy and high acid secretion is associated with duodenal
ulcers, while infection with atrophy and low acid secretion increases the risk of
gastric cancer ofthe intestinal-type.
INTRODUCTION
Before Helicobacterpylori was discovered, the aetiology and treatment ofduodenal
ulcer [DU]b disease was viewed in terms ofthechanges in gastric physiology found in DU
patients. Since it became clear that H. pylori also plays a major role, we and others have
examined the respective roles of, and interactions between, physiology and infection in a
variety ofconditions. What has emerged is that H. pylori is actually responsible for many
of the physiological changes previously described in DU patients. Furthermore, it is
becoming clear that how infection affects gastric physiology in a particular host is an
important determinant ofthe different outcomes ofH. pylori infection.
REGULATORY PEPTIDES AND THEIR RECEPTORS
Three regulatory peptides seem especially interesting in the pathophysiology ofpep-
tic ulcer disease and H. pylori infection:
Gastrins
Gastrins [1] are released from G-cells. These are located in the epithelium ofthe gas-
tric antrum and duodenum, but are more abundant in the former. The main gastrin pep-
tides are gastrin-34 (G34) and its C-terminal fragment gastrin-17 (G17). About 95 percent
of antral gastrin is G17, while duodenum gastrin is about 60 percent G34 [2]. G34 and
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G17 have similar agonist activity at the gastrin (alias CCK-B) receptor [3]. However, G34
is cleared more slowly from the circulation, so that if the same molar amount of G34 or
G17 are administered in vivo, G34 has the greatereffect [3]. G-cells are ofthe "open type"
with microvilli extending into the gastric lumen. G-cells are stimulated to release gastrin
by luminal stimuli, notably the products of protein digestion and intra-mucosal stimuli,
notably gastrin-releasing peptide [1]. Gastrin acts via the blood stream to increase acid
secretion. It does this both directly by stimulating parietal cells [4] and indirectly by stim-
ulating ECL-cells to release histamine [5]. Gastrin also has a trophic effect on the gastric
epithelium and particularly on the ECL-cells that it contains [6]. Prolonged hypergastri-
naemia can cause ECL-cell tumors.
Somatostatins
Somatostatin peptides [7] are released from D-cells located throughout the gastroin-
testinal tract and many other organs. The two main forms of somatostatin S28 and S14
havedifferentaffinities forthe different somatostatin receptors SSTR1-5. Recentevidence
suggests that SSTR2 is most involved in physiological control ofacid secretion [8]. This
receptor appears to be affected similarly by S28 and S14. D-cells in the gastric antrum are
"open," with microvilli extending into the gastric lumen, while D-cells ofthe gastric cor-
pus are "closed" and do not contact the lumen [7]. Somatostatin is released from the
antrum by luminal factors, notably acid [9-11], but also by food [12]. Curiously, although
antral D-cells are in contact with the gastric lumen, there is evidence that acid affects
antral D-cells indirectly through a neural reflex that may involve CGRP [13].
Somatostatin is also released by neurotransmitters including epinephrine and a wide vari-
ety ofpeptides including gastrin releasing peptide (GRP)/bombesin and cholecystokinin.
Stimulation ofsomatostatin-release by small intestinal hormones such as cholecystokinin
may be important in the inhibition ofgastric secretion that occurs in the late postprandial
period. Somatostatin has widespread inhibitory effects on endocrine and exocrine cells,
including G-cells, ECL-cells and parietal cells [7].
Gastrin-releasing peptide
GRP [14] contains 27 amino acid residues. Its C-terminal decapeptide GRP1O also
occurs in humans and has been called neuromedin-C [15]. GRP closely resembles the
amphibian 14 amino acid-peptide bombesin. GRP is present in nerve fibers and cell bod-
ies throughoutthe gastrointestinal tract, in otherorgans and within the central nervous sys-
tem. GRP nerves are present in the oxyntic and antral regions ofthe stomach, but are more
abundant in the former [16]. GRP is an exceedingly potent stimulant of gastrin release,
and there is good evidence that it mediates gastrin release in response to vagal stimulation
[17]. GRP also stimulates somatostatin release from gastric mucosal pieces in vitro. These
appear to be indirect effects, mediated via gastrin-release in the antrum and via choliner-
gic and non-cholinergic mucosal nerves in the corpus [18]. Infusion of GRP into intact
animals both stimulates acid secretion through gastrin release and also inhibits it [19],
probably by releasing somatostatin in the gastric corpus [14]. Thus, GRP not only stimu-
lates acid secretion via gastrin but can also inhibit acid secretion via somatostatin, which
inhibits gastrin release in the antrum and acid secretion in the corpus through separate
mechanisms.
KNOWLEDGE BEFORE THE DISCOVERY OF H. PYLORI
Much ofthe work on gastric pathophysiology was undertaken before the discovery of
H. pylori. The subsequent discovery of this bacterium has taught us much, most notably
we have learned the importance of integrating physiology with other disciplines such as
bacteriology, immunology and histopathology.
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Acid in DU disease
Before the discovery of H. pylori, our whole approach to DU disease was based on
the finding that sufferers secrete more acid than controls. This abnormality could be divid-
ed into two elements: First, duodenal ulcer patients have been estimated to have approxi-
mately two billion parietal cells compared with about one billion in controls, leading to a
maximal acid-secretory capacity that is about twice normal [20, 21]. In addition, studies
showed a series of abnormalities of physiological control that might be summarized as
failures of inhibitory reflexes. Basal acid secretion was increased even more than would
be expected from the increased parietal cell mass [20]. A low intra-gastric pH inhibited
peptone-stimulated acid secretion less than usual [22], and perhaps because of this, acid
secretion persisted for longer than usual after meals [23]. Additionally, acid-secretion in
response to GRP/bombesin was found to be exaggerated in DU patients. More precisely
an inhibitory effect ofhigh doses appeared lacking in DU patients [24,25].
Abnormalities ofgastrin physiology in duodenal ulcer disease
Since gastrin is the most potent known stimulant of acid secretion, it was logical to
ask whether its release was increased in DUpatients, but studies gave mixed results. Some
centers reported higher postprandial gastrin concentrations in DU patients [26], but others
did not. In retrospect, this probably depended on whether the control group was infected
with H. pylori or not. Studies using intra-gastric titration showed that a low intra-gastric
pH inhibited peptone-stimulated gastrin levels less in DU patients than in controls [22].
One stimulus that consistently produced higher plasma gastrin levels in DU patients than
controls was bombesin [24, 25].
Abnormalities ofsomatostatin in duodenal ulcer disease
Decreased mucosal somatostatin was a more consistent finding in DU disease.
Studies showed less immuno-reactive somatostatin and fewer immuno-reactive D-cells in
DU patients [27]. This was particularly interesting because it offered an explanation for
the failure of acid-inhibitory reflexes in DU patients. However, the cause of decreased
mucosal expression of somatostatin in DU disease remained mysterious until the discov-
ery ofH. pylori.
EFFECTS OF H. PYLORI ON HORMONES
When it became clear that H. pylori is a major etiologic factor in DU disease, we and
others asked whether this infection causes some or all ofthe alterations in gastric physi-
ology that had been reported in DU disease.
Gastrin
Odera et al. [28] reported that elevated gastrin levels in children with H. pylon fall
after treatment. However they did not measure acid secretion, so it was unclear whether
elevated gastrin levels were due to the achlorhydria ofinitial infection, which resolved on
treatment. Wereportedelevatedpostprandial gastrin levels andelevatedmaximal acid out-
put in infected vs. uninfected DU patients and proposed the "gastrin link" between infec-
tion ofthe antrum and ulcers in the duodenum in 1989 [29]. We and others confirmed that
gastrin levels fall on eradication of the infection. The elevation in plasma gastrin levels
occurs basally and during infusion of bombesin or GRP [26, 30, 31]. Interestingly, the
excessive rise in gastrin after GRP [30] and aftereating [32] ispredominantly due to arise
in G17. This might be because the excessive gastrin emanates from the antrum where G17
predominates. Alternatively H. pylori might accelerate the cleavage of gastrin to release
G17. Eradication restores the inhibitory effect of cholecystokinin on gastrin release [33]
This reflex is believed to be mediated through release ofsomatostatin from antral D-cells.
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Somatostatin
Several studies have shown that the decrease in mucosal expression of somatostatin
noted in DU patients is actually due to H. pylori infection. Originally Kaneko et al. [34]
showed diminished mucosal somatostatin peptide in association with this infection, and
Moss et al. [35] showed that H. pylori infection also decreases mucosal somatostatin
mRNA andthe numberofimmunoreactive D-cells. Other groups have sinceconfirmed the
inhibitory effect of H. pylori on mucosal levels of somatostatin peptide [36-38], mRNA
[37] and D-cell numbers [39]. On the other hand, Graham et al. [40] were unable to detect
a difference in the number of D-cells. Such discrepancies might emanate from technical
aspects such as the ability to detect cells containing small amounts of peptide. Little is
known of D-cell function in H. pylori infection. We compared the response of mucosal
somatostatin mRNA to three-hour infusions ofGRP between infected and uninfected per-
sons [41]. The results showed a significant rise in somatostatin mRNA in the infected, but
not in the uninfected, group. The reason for this difference awaits elucidation, but base-
line somatostatin mRNA levels were considerably diminished in the infected group, so the
difference might be due to diminished autoinhibition of D-cells by somatostatin itself
[42]. Whatever the explanation, the results do show that D-cells are capable of respond-
ing to GRP in H. pylori infection.
HORMONE-RELATED EFFECTS ON ACID SECRETION
Acid secretion in H. pylori infection has several quite clearly defined facets that need
to be considered separately. The resultis that H. pylori can both increase anddecrease acid
secretion.
Epidemic achlorhydria onfirst infection
Acid secretion is drastically diminished or completely absent for several weeks after
first infection with H. pylori. This was first noted in volunteers undergoing repeated intu-
bation. It was later realized that this was due to transmission ofH. pylori between the sub-
jects [43]. Achlorhydria might be due to acid-suppressing factors released by H. pylori.
These were identified by Cave and his colleagues [44, 45] but have not been not fully
characterized. They are discussed by Dr. Cave (page 91).Alternatively the immunological
response to H. pylori might be responsible for the suppression ofacid secretion. Patients
with other infections such as pneumonia also show achlorhydria [46], and certain
cytokines including interleukin-1 [47, 48] and tumor necrosis factor-a [49] inhibit acid
secretion.
Diminishedacid secretion through gastric atrophy
Epidemiological studies show that H. pylori gastritis can progress to atrophic gastri-
tis and intestinal metaplasia [50, 51]. Atrophy developed in 28 percent ofinfected patients
compared with four percent of uninfected patients over an 11-year period in Amsterdam
[52]. Atrophy leads to a loss ofparietal cells and acid secreting capacity. It is not current-
ly clear whether atrophy is reversible on eradicating H. pylori, but ifthis is true, as Borody
suggests [53], acid secretion might rise after eradication of H. pylori from patients with
infection and atrophy.
Defective inhibition ofacid secretion in H. pylori infection
Studies have shown that H. pylori infection is associated with defective inhibition of
acid secretion. Elevations of acid secretion under conditions that would normally inhibit
this may be due to a paucity of the inhibitory peptide somatostatin in the gastric mucosa.
We found that eradication ofH. pylori decreases basal acid secretion to about one third of
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pre-eradication values in DU patients [54]. The sensitivity of parietal cells to gastrin-17
did not change [54], and the fall in acid secretion was appropriate for the accompanying
fall in circulating gastrin. We also found that H. pylori impairs inhibition ofpeptone-stim-
ulated acid secretion by a low intragastric pH. The low pH suppressed acid secretion by
greater than 80 percent in uninfected persons but by less than 50 percent in infected vol-
unteers. Thus, the infection elevated acid secretion in response to the acidic meal by about
three times [55]. Acid secretion stimulated by neutral peptone was similar in the infected
and uninfected groups, indicating that the abnormality lies in the inhibitory pathway.
Antral distension normally inhibits pentagastrin-stimulated acid secretion, and this reflex
is also attenuated by H. pylori infection [56]. Infusions of GRP normally exert a mixture
of stimulatory and inhibitory effects on acid secretion. Stimulation is through gastrin
release, while inhibition may be through somatostatin [18], which exogenous GRP prob-
ably releases indirectly via several routes including locally released gastrin, mucosal
nerves, small intestinal hormones and a low intragastric pH [see above]. Acid secretion
stimulated by GRP is elevated about three times in H. pylori infection and about six times
in DU persons when compared with uninfected controls [57]. The more marked elevation
of acid secretion in DU patients might be due to their greater parietal cell mass (see
above). Elevated GRP-stimulated acid secretion disappears slowly during the first year
after successful eradication. H. pylori-related elevations in acid secretion are interesting
because they might be responsible for the association between this infection and DU dis-
ease. Therefore, it is important to ask whether the changes are sufficient to affect the pH
in the duodenum? Hamlet et al. [58] found that infected persons did indeed have a lower
intra-duodenal pH during the second hour after neutral and acidic meals than healthy con-
trols. However, this was at least partly due to rapid gastric emptying, in addition to
changes acid secretion. The findings described so far in this paragraph can largely be
explained by H. pylori decreasing expression of somatostatin in the gastric mucosa, but
Accord's interesting finding also needs to be considered. He found that basal acid secre-
tion is higher in patients with active DUs, than in patients with inactive DUs [59], with-
out eradication of H. pylori. This raises the possibility that the ulcer itself stimulates acid
secretion, perhaps through a neural reflex. Alternatively the physiological abnormality in
DU disease might be cyclical, with ulcers occurring when acid secretion is greatest.
However, this cannot be the whole story because H. pylori infection is associated with ele-
vated acid secretion during stimulation with acid-peptone and GRP, even in patients with-
out ulcers [55, 57].
REASONS FOR DIFFERENT RESPONSES IN DIFFERENT PATIENTS
The amount of acid secreted by a particular patient presumably depends on the rela-
tive contribution ofthe various inhibitory and stimulatory processes described above. This
merits study because the amount ofacid secreted may be an important determinant ofdis-
ease outcome in H. pylori infection. For example, we do not know why acid secretion is
lost initially but then returns. Does acid secretion return because of a change in the state
of the bacterium or the host's response to it? Similarly, why is acid secretion diminished
by gastric mucosal atrophy in some patients but not in others? This depends partly on the
time since infection. But atrophy also seems more likely if the infecting strain is CagA+
[60] and if the host is HLA-DR5 [61]. Other atrophy-producing factors, such as a high-
salt diet [62] may also be involved. One important finding from Finland is that DU
patients have arelative lack ofcorpus atrophy [51], the so-called "juvenile mucosa." Thus,
DU patients might have a greater parietal cell mass because their parietal cells have not
been diminished by atrophy [20]. Alternatively, the greater parietal cell mass might be in
inherited trait or due to the trophic effect of gastrin [6]. In that case, the relative lack of
corpus gastritis could be due to high acid secretion inhibiting the onset of atrophy, rather
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than the reverse. This notion is supported by the increase in atrophy that is seen after sup-
pression of acid secretion with potent agents such as omeprazole [63]. In view of these
possibilities, it has been interesting to ask whether maximally stimulated acid output
changes following eradication ofH. pylori from different groups ofpatients. DU patients
may be mostlikely to show a fall because theirgastric corpus is initially relatively healthy
and secreting plenty of acid. At present, the data are conflicting. Groups in Glasgow [64]
and South Africa [65] found no significant change in maximal acid output seven months
and 12 months, respectively, after eradication of H. pylori from DU patients. However,
groups in London [66] and Canada [67] saw significant falls at six and 12 months. Such
discrepancies are presumably due to methodological differences between the studies.
MECHANISMS OFALTERED HORMONE PHYSIOLOGY
Products ofurease
We originally proposed that alkali generated locally by H. pylori's urease increases
gastrin release [29]. As acid is a major D-cell stimulant, this would be expected to
decrease expression of somatostatin [9, 68] and could thus produce the observed increas-
es in gastrin and acid. Measurements of the pH in the gastric mucus layer in H. pyloni
infection have shown it to be more alkaline, although the difference is only 0.3-0.8 of a
pHpoint [26]. Increasing intra-gastric ureadid notelevategastrin in infected persons [31],
but might not be expected to do so because urease's Km of0.2 [69] is well below the nor-
mal intra-gastric concentration of urea which is 1-2.5 mmol/l, so the enzyme is already
virtually saturated with substrate. Inhibition of urease either using acetohydroxamic acid
[70] orbismuthplus antibiotics did notdecrease gastrin release in short-term experiments.
Taken together, these results do argue quite strongly against the role of ammonia.
However the possibility cannot be dismissed altogether because some ammonia produc-
tion persisted during the study with acetohydroxamic acid [70], and it may be that expo-
sure to small amounts is sufficient. Also, if alkalinization is involved the duration of the
studies may have been insufficient. Plasma gastrin levels remain considerably elevated
three hours after acidification ofthe stomach ofachlorhydric patients [71].
Ammonium ions may release gastrin independent ofany effect on pH. Lichtenberger
et al. found elevatedplasmagastrin levels in rats whose diets had been supplemented with
ammonium acetate for two weeks.Astudy fromJapan suggests thatmonochloramine may
be a more potent stimulant ofgastrin release than ammoniaitself [72]. Ammoniareleased
by H. pylori activates neutrophils to create oxidative bursts in vitro [73]. Oxidation of
hydrochloric acid by neutrophils would be expected to produce hypochlorous acid, which
then reacts with ammonia to produce monochloramineNH2Cl. In short, it is currently dif-
ficult to dissect the respective roles of ammonium ions, alkalinization and monochlo-
ramine, largely due to a lack ofadequate methods to selectively eliminate these factors in
humans.
Thepossible role ofinflammatory mediators
Another possibility is that cytokines released in H. pylori gastritis are responsible for
the altered endocrine cell function. H. pylon infection increases mucosal expression of
many cytokines including; interleukins 1 , 6 and 8, tumor necrosis factor-a, interferon-y
andplateletactivating factor [74]. Severalcytokines releasegastrin from antral preparations
in vitro, including interleukins 1 and 2, tumor necrosis factor-a interferon-y and
leukotrienes C4 andD4. We found thattumornecrosis factor-aandinterferon-y release gas-
trin from canine antral endocrine cells in primary culture [75]. Diffusible products of
human peripheral blood mononuclear cells (lymphocytes plus monocytes) had a stronger
effect [75]. This might be because the above cytokines have additive or synergistic effects
when given together or because some other product of mononuclear cells is actually
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involved. This is distinctly possible because the number of known cytokines is rapidly
expanding. Those mentioned above were studied largely because assays are available, and
these are known to affect a wide variety ofother types ofcells. One study demonstrates the
importance ofsynergism between stimuli: H. pylori sonicates failed to release gastrin from
canine antral cells but markedly stimulated G-cells primed with interleukin-8. This
chemokine given alone was arelatively weak stimulant ofgastrin release [76]. Interestingly
the response to interleukin-8 plus H. pylori extract varied between strains of H. pylon.
Another study showed the importance of the duration of cytokine-exposure. Short term
treatment of canine corpus D-cells to TNF-a weakly stimulated somatostatin release, but
exposure for 6 to 24 hr decreased both cell content and percent release of somatostatin in
response to specific stimuli [77].
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Figure 1. Some mechanisms affecting acid secretion inH.pyloni infection. Gastrin from G-cells
(G) stimulate parietal cells (P) to secrete acid, partly by stimulating enterchromaffin cells (ECL) to
release histamine. D-cells (D) in the gastric corpus and antrum release somatostatin, which inhibits
G-, ECL- and parietal cells. Cytokines including tumor necrosis factor-a (TNFa), interferon-y
(INFy) and interleukin-8 (IL-8) may cause these changes in G- and D-cell function, which tend to
increase acid secretion. However, H. pylori can also decrease acid secretion, by direct effects on
parietal cells by causing atrophy and through cytokines such asinterleukin-1IO (ILI3).
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CLINICAL PERSPECTIVE AND FUTURE STUDIES
It is now clear that H. pylori infection can both increase and decrease acid secretion.
These different responses seem important clinically because elevation ofacid secretion is
found in duodenal ulcerpatients, and the excess ofacid may actually cause the ulcers. On
the other hand, diminished acid secretion is found in patients with gastric cancer and may
promote carcinogenesis by allowing the stomach to become chronically colonized with
other bacteria that produce mitogens. Exploration of the mechanism of these changes in
acid secretion has shown that H. pylori infection alters the function of gastric endocrine
and exocrine cells. Future studies should aim to elucidate the molecular and cellular basis
of these changes and the reasons why these effects differ between individuals.
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